The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Download your free eBook: How to overcome cross-reactivity in Zika virus research

Zika virus poses a significant global risk, with the World Health Organization (WHO) declaring it a public health emergency of international concern in 2016.

Currently, there is no vaccine or specific treatment available, with a major challenge in developing good diagnostic assays for the virus being its close structural relationship to Dengue virus.

This has led to:

  • Challenges for academic research with accurately identifying Zika-positive samples, affecting publication and funding.
  • Difficulties with the public health management of the virus, as a lack of reliable serological methods make accurate epidemiological data difficult to obtain.
  • Issues for pharmaceutical companies needing to balance the costs of pharmaceutical development with the urgent need to bring drugs and vaccines to market.

In this eBook, we discuss these issues, and ways in which academic, pharmaceutical and public health institutes can overcome the cross-reactivity challenge in Zika virus research.

Simply fill out the form below to get your copy.

Would you like to be kept informed of the latest news and innovations from the infectious disease community? Please let us know if you would like us to contact you or not by selecting one of the options below.

8 + 8 =